Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase II open label, non comparative, non randomized study for the assessment of the efficacy and safety of lenalidomide + adriamycine and low dose dexamethasone combination (RAD) in newly diagnosed, symptomatic multiple myeloma patients who are eligible for high dose therapy and autologous stem cell transplantation.

Next Previous
Trial Profile

A phase II open label, non comparative, non randomized study for the assessment of the efficacy and safety of lenalidomide + adriamycine and low dose dexamethasone combination (RAD) in newly diagnosed, symptomatic multiple myeloma patients who are eligible for high dose therapy and autologous stem cell transplantation.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 17 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dexamethasone (Primary) ; Doxorubicin (Primary) ; Lenalidomide (Primary) ; Low molecular weight heparins; Zoledronic acid
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Acronyms RAD

    • Most Recent Events

    • 25 Jun 2017 Final results of the Greek Myeloma Study Group, presented at the 22nd Congress of the European Haematology Association
    • 06 Dec 2016 Results (cut off data February 2016, n=45) assessing efficacy of RAD as induction therapy for NDMM patients, presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
    • 14 Oct 2016 Status changed from active, no longer recruiting to completed.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top